Thirty-eight elderly female subjects (aged 80 ± 7 years, mean ± standard deviation) were randomized to immunization with trivalent inactivated influenza virus vaccine containing either purified surface antigen (n = 18) The population aged 65 years or older includes most of the patients at highest risk for serious medical complications following influenza virus infection and is therefore targeted for annual influenza immunization (10). Attention is being given to defining vaccination strategies which can result in optimal immune responses and enhanced protection in the elderly (18). Influenza vaccine efficacy is best correlated with the production of antibodies directed against the hemagglutinins (HAs) of the vaccine strains (17). In addition to humoral responses, immunization also elicits antigen-specific T-cell-mediated immune responses which are measurable in terms of increased cell proliferation (4), lymphokine secretion (5, 12), and/or cytotoxicity (6, 13, 20) (3, 15, 21, 22) . Published data for humans are also inconsistent regarding whether subunit vaccines differ from whole-virus preparations in their respective abilities to elicit cytotoxic T lymphocyte (CTL) responses (6, 13). These observations prompted me to examine whether immunization of elderly adults with surface antigen vaccine (SAV) stimulates humoral and CTL responses which are comparable to those elicited by whole-virus vaccine (WVV). 
hemagglutination inhibition antibodies and cytotoxic T lymphocyte (CTL) activity at 0 and 3 weeks postvaccination. Serological responses to both of the type A vaccine strains following immunization with surface antigen vaccine (SAV) were significantly more frequent and greater in magnitude than those induced by whole-virus vaccine. Antibody responses to the B/Panama component were modest and did not differ significantly between the two vaccines. Persons given SAV, but not those given whole-virus vaccine, had a small but significant increase in mean percent specific lysis of influenza A (HlNl) virus-infected autologous targets by peripheral blood mononuclear cells which were stimulated in vitro with influenza A (HINI) virus. The HlNl-stimulated cytotoxic effectors induced by SAV were CD8+ and were not cross-reactive against H3N2-infected targets. Influenza B virus-specific CTL responses were not observed with either vaccine. These results suggest that currently available subunit influenza virus vaccines may offer an advantage over inactivated whole-virus preparations for inducing humoral and cellular immune responses in the elderly, although the CTL response may be too limited to be of physiological significance.
The population aged 65 years or older includes most of the patients at highest risk for serious medical complications following influenza virus infection and is therefore targeted for annual influenza immunization (10) . Attention is being given to defining vaccination strategies which can result in optimal immune responses and enhanced protection in the elderly (18) . Influenza vaccine efficacy is best correlated with the production of antibodies directed against the hemagglutinins (HAs) of the vaccine strains (17) . In addition to humoral responses, immunization also elicits antigen-specific T-cell-mediated immune responses which are measurable in terms of increased cell proliferation (4), lymphokine secretion (5, 12) , and/or cytotoxicity (6, 13, 20) (3, 15, 21, 22) . Published data for humans are also inconsistent regarding whether subunit vaccines differ from whole-virus preparations in their respective abilities to elicit cytotoxic T lymphocyte (CTL) responses (6, 13 (20) . These viruses were used in place of strains homologous to the vaccine components for CTL assays because of the expectation that cytolytic effectors induced in bulk cultures would be crossreactive between antigenically drifted variants.
Influenza virus-specific CTL assay. Experimental conditions for the induction and assay of influenza virus-specific CTL were exactly as previously described (20) . In brief, freshly isolated responder PBMC (2 x 107) were cultured for 7 days in the presence of autologous stimulator cells (5 x 106) that had been infected with influenza A/Taiwan (HlNl) or B/Yamagata virus or that had been mock infected with allantoic fluid from uninfected eggs. PBMC to be used for target cells were incubated for 7 days in a complete medium to which 5 ,ug of phytohemagglutinin per ml was added 3 days after the initiation of culture. On the morning of the cytotoxicity assay, phytohemagglutinin-activated lymphoblasts were harvested and infected with influenza A/Taiwan (H1N1), A/Shanghai (H3N2), or B/Yamagata virus or were mock infected with allantoic fluid. Following infection, target cells were radiolabelled with 100 p,Ci of sodium [5"Cr] (1, 7) . It is noteworthy autologous targets that had been either infected with influenza than exhibiting heterosubtypic cross-reactivity against H3N2-The mechanisms which underlie these effects are not known, infected targets. The difference between SAV and WVV although there is clearly substantial variability between vacgroups in the magnitude of the HlNl-specific CTL response to cines and subject populations which may confound interstudy immunization was not statistically significant. Increases in the comparisons. Since inactivated influenza vaccines are stanmean levels of cytolytic activity by effector cells from influenza dardized according to HA content, variability in antigen dose is B virus-stimulated or unstimulated bulk cultures were genernot likely to account for the differences in serum HAI antibody ally negligible (Fig. lb and c) .
responses between SAV and WVV recipients. Moreover, the administration of higher-than-usual doses of inactivated influ-DISCUSSION enza vaccine has been previously shown to have little if any effect on serum HAI antibody responses in elderly subjects (9, Using commercially available inactivated influenza virus 14). On the other hand, disruption of intact virions and further vaccines, I have observed that elderly volunteers mount signifpurification of envelope glycoproteins may induce HA aggre- gation and/or conformational changes which enhance the antigenicity of a subunit preparation in primed subjects. It is also possible that host factors, including the latency and/or multiplicity of a prior vaccination(s) with similar virus antigens, influence the relative immunogenicity of SAV compared with that of WVV. Even after baseline antibody titers have been taken into account, antecedent immunization appears to be associated with some blunting of subsequent vaccine responses in elderly adults (2, 16) and may account for the relative advantage of subunit influenza virus vaccines in this population. Further studies to examine these possibilities are warranted.
The CTL response to vaccination was of low magnitude and was apparent only in the group of subjects given SAV. These data contrast with earlier reports in which virus-stimulated effector cells from young adult recipients of inactivated wholevirus preparations had clear-cut rises in mean %SL of targets infected with homotypic virus (6, 13 In conclusion, the present results demonstrate that alternative forms of commercially available influenza virus vaccine cannot be assumed to stimulate equivalent serological responses when administered in standard doses to immunologically primed adults. Specifically, vaccines which contain purified influenza virus surface antigens may offer an advantage over whole-virus preparations for immunization of the elderly. On the other hand, the overall weight of published evidence, including this study, suggests that CTL responses to conventional inactivated influenza virus vaccines are quite limited. Given the demonstrated role of CTL in promoting viral clearance and host recovery following influenza virus infection, future efforts will need to be directed toward the design of vaccines which are better able to elicit CTL memory. Such vaccines may be particularly important for use in high-risk elderly patients, who have diminished levels of cellular immunity to influenza virus (11, 19) .
